Back
Anti-TNF alpha medications and neuropathy.
Journal article

Anti-TNF alpha medications and neuropathy.

  • Tsouni P Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Bill O Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Truffert A Division of Neurology, Department of Clinical Neurosciences, University Hospital of Geneva (HUG), Geneva, Switzerland.
  • Liaudat C Department of Rheumatology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Ochsner F Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Steck AJ Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Kuntzer T Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Show more…
  • 2015-08-27
Published in:
  • Journal of the peripheral nervous system : JPNS. - 2015
anti-TNF alpha
demyelination
inflammation
neuropathies
Adalimumab
Adult
Aged
Autoimmune Diseases
Electrodiagnosis
Etanercept
Female
Humans
Infliximab
Male
Middle Aged
Neural Conduction
Peripheral Nervous System Diseases
Rheumatic Diseases
Tumor Necrosis Factor-alpha
English We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti-tumor necrosis factor alpha (a-TNF) medications-induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a-TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person-years. The median time from a-TNF medication treatment to ATIN was 16.8 months (range 2-60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a-TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was "inflammatory", suggesting that it could be due to systemic pro-inflammatory effects of a-TNF agents.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/215515
Statistics
Document views: 23 File downloads: